Vera Therapeutics Reports Q3 2026 Results Following TRUTAKNA Commercial Launch

Vera Therapeutics reported its third quarter 2026 financial results, highlighted by the initial commercial performance of TRUTAKNA following its accelerated approval in July 2026. The company recorded net product revenue of $10.3 million, which was split equally between direct patient demand and distributor inventory stocking. Early adoption is evidenced by approximately 700 patient start forms. Despite the revenue growth, the company reported a net loss of $93.7 million ($1.30 per share), driven by significant increases in selling, general, and administrative expenses to support the commercial rollout. However, Vera maintains a strong liquidity position with $459 million in cash and marketable securities following a recent debt drawdown. The company is focused on expanding market access, aiming for 50% coverage of commercially insured lives by year-end.

9 articles from 3 sources · updated

Coverage